Biocompatibles gets share price boost after bead patent buy
This article was originally published in Clinica
Executive Summary
Shares in UK oncology specialist Biocompatibles International reached their highest price in nearly five years after the firm bought patents protecting its bead products. As Clinica went to press, Biocompatibles’ share price had reached 273.50p on the London Stock Exchange during morning trading – the company’s highest value since September 2005.